28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
This study showed that subcutaneous etanercept (50 mg/wk) was well tolerated in this small group of patients with Alzheimer disease dementia, but a larger more heterogeneous group needs to be tested before recommending its use for broader groups of patients. 4 key findings →
Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Patients with severe AD demonstrated greater efficacy compared to placebo on measures of cognition and global function. 3 key findings →
Participants: 176 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There was no difference in the age (mean [SD], 74.17 [7.96] years), sex (12 women [67%]), or baseline Mini-Mental State Examination score (mean [SD], 19.39 [3.24]) between the crossover (n = 9) and open-label groups (n = 9). 3 key findings →
Design: open-label trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In this review of 56 RCTs for AD involving 39 575 participants, 23 348 women (59.0%) were included. 5 key findings →
Design: systematic review Participants: 100 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Goals-of-care documentation during the intervention phase occurred among 3744 of 6023 patients (62.2%) compared with 2396 of 4779 patients (50.1%) in the usual care phase (P Conclusions and relevance In this stepped-wedge cluster randomized clinical trial of older adults, a GOC video intervention delivered by PCEs resulted in higher rates of GOC documentation compared with usual care, including among Black or African American individuals, Hispanic or Latino individuals, non-English speakers, and people living with Alzheimer disease and related dementias. 3 key findings →
Participants: 802 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among 80 participants (mean [SD] age, lithium: 72.93 [8.77] years; placebo: 71.22 [6.47] years; 56% female), none of the 6 coprimary outcomes met the prespecified significance threshold. 2 key findings →
Participants: 170 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Inflammatory mechanisms have been implicated in Alzheimer's disease (AD) and might be mediated via the COX-2 enzyme. 3 key findings →
Participants: 725 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among community-living dyads, a nonpharmacologic biobehavioral environmental intervention compared with control resulted in better outcomes for COPE dyads at 4 months. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Donepezil is safe and well tolerated. 1 key finding →
Design: clinical trial Participants: 35 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The study enrolled 181 participants (mean [SD] age, 69.6 [7.2] years; 114 [63.0%] female): 91 to the intervention arm (depression in later life [DIL] intervention) and 90 to care as usual (CAU). 1 key finding →
Participants: 181 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A statistically significant age-adjusted association was observed between the A1C level and the score on all four cognitive tests. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mild cognitive impairment (MCI) increases dementia risk with no pharmacologic treatment available. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Aerobic exercise has shown inconsistent cognitive effects in older adults with Alzheimer's disease (AD) dementia. 4 key findings →
Design: randomized controlled trial Participants: 96 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Participants allocated to CR received 10 weekly sessions over 3 months and four maintenance sessions over 6 months. 4 key findings →
Design: randomized controlled trial Participants: 475 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
African heritage diets are increasingly being replaced by Western-style dietary patterns because of urbanization, economic development, increased access to processed foods, globalization and changing social norms. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Between May 18, 2021, and Sept 8, 2023, 9981 participants were screened, of whom 3808 were randomly assigned; 1855 in evoke (semaglutide, n=928; placebo, n=927) and 1953 in evoke+ (semaglutide, n=976; placebo, n=977). 5 key findings →
Design: clinical trial Participants: 928 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Cognitive training involving speed of cognitive processing has the potential to delay the diagnosis of ADRD. 1 key finding →
Design: randomized controlled trial Participants: 2,021 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The treatment of Alzheimer's disease (AD) in the field of non-pharmacological interventions is a challenging issue, given the limited benefits of the available drugs. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Home-based CCT with adaptive difficulty and personal tailoring appears superior to more generic CCT in relation to both cognitive and non-cognitive outcomes. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
The HBA-CT program improves cognitive, mood, and sleep functions in older adults 'at risk' of dementia, and therefore offers promise as a secondary prevention strategy. 1 key finding →
Participants: 64 Evidence: high
Full summary, score breakdown and related studies → Original source
We developed and evaluated the effect of Multimodal Cognitive Enhancement Therapy (MCET) consisting of cognitive training, cognitive stimulations, reality orientation, physical therapy, reminiscence therapy, and music therapy in combination in older people with mild cognitive impairment (MCI) or mild dementia. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
The traditional Mediterranean diet (MedDiet) has shown beneficial effects on cognitive decline. 4 key findings →
Design: randomized controlled trial Participants: 522 Evidence: high
Full summary, score breakdown and related studies → Original source
This study gives evidence that cognitive training may be effective to prevent cognitive decline and onset of MCI in PD patients. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Aerobic exercise combined with computerized cognitive training has better effects on the cognitive functional status of survivors of stroke than an active control. 1 key finding →
Design: randomized controlled trial Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source
Our study demonstrates the feasibility of a group-based Cognitive Rehabilitation program for patients with mild AD dementia. 3 key findings →
Participants: 16 Evidence: high
Full summary, score breakdown and related studies → Original source
10 of the 1,875 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →